BlackRock
JANX icon

BlackRock’s Janux Therapeutics JANX Stock Holding History

BlackRock’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94.2M Buy
6,134,667
+701,434
+13% +$10.2M ﹤0.01% 2258
2026
Q1 		$75.5M Buy
5,433,233
+1,353,033
+33% +$18.6M ﹤0.01% 2275
2025
Q4 		$56.3M Buy
4,080,200
+349,206
+9% +$8.21M ﹤0.01% 2447
2025
Q3 		$91.2M Buy
3,730,994
+328,147
+10% +$7.99M ﹤0.01% 2156
2025
Q2 		$78.6M Buy
3,402,847
+529,888
+18% +$14M ﹤0.01% 2204
2025
Q1 		$77.6M Buy
2,872,959
+147,146
+5% +$5.55M ﹤0.01% 2143
2024
Q4 		$146M Buy
2,725,813
+303,177
+13% +$16M ﹤0.01% 1846
2024
Q3 		$110M Buy
2,422,636
+78,629
+3% +$3.42M ﹤0.01% 2029
2024
Q2 		$98.2M Buy
2,344,007
+650,016
+38% +$30.5M ﹤0.01% 2037
2024
Q1 		$63.8M Sell
1,693,991
-68,110
-4% -$1.48M ﹤0.01% 2309
2023
Q4 		$18.9M Buy
1,762,101
+122,522
+7% +$1.06M ﹤0.01% 3043
2023
Q3 		$16.5M Buy
1,639,579
+444,991
+37% +$5.13M ﹤0.01% 3055
2023
Q2 		$14.2M Buy
1,194,588
+59,943
+5% +$801K ﹤0.01% 3241
2023
Q1 		$13.7M Buy
1,134,645
+31,590
+3% +$526K ﹤0.01% 3159
2022
Q4 		$14.5M Sell
1,103,055
-147,293
-12% -$2.16M ﹤0.01% 3196
2022
Q3 		$16.9M Buy
1,250,348
+41,994
+3% +$561K ﹤0.01% 3124
2022
Q2 		$14.8M Buy
1,208,354
+46,633
+4% +$552K ﹤0.01% 3264
2022
Q1 		$16.7M Buy
1,161,721
+153,460
+15% +$2.51M ﹤0.01% 3289
2021
Q4 		$19.9M Buy
1,008,261
+206,483
+26% +$4.33M ﹤0.01% 3277
2021
Q3 		$17.3M Buy
801,778
+691,831
+629% +$19.9M ﹤0.01% 3381
2021
Q2 		$2.74M Buy
+109,947
New +$2.45M ﹤0.01% 4135

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock's JANX Position: Q2 2026 in Review

BlackRock increased its Janux Therapeutics (JANX) stake by 13% in Q2 2026, buying an estimated $10.2M and bringing the position to 6,134,667 shares worth $94.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2258.

BlackRock first reported a position in JANX in Q2 2021 and has held it in 21 quarters since. The position peaked at $146M in Q4 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • BlackRock held 6,134,667 shares of Janux Therapeutics worth $94.2M as of Q2 2026.
  • BlackRock bought 701,434 Janux Therapeutics shares in Q2 2026, an estimated $10.2M.
  • Janux Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2258 holding.
  • BlackRock first reported a position in Janux Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • BlackRock's Janux Therapeutics position peaked at $146M in Q4 2024.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.